Identification of 4-[4-(4-Fluoro-Phenyl)-Thiazol-2-Ylamino]-2,6-Dimethyl-Phenol (KR-33749) as an Inhibitor of 5-Lipoxygenase with Potent Antiinflammatory Activity

被引:5
作者
Cho, Young Sik [2 ]
Kim, Chi Hyun [2 ]
Surh, Ji Hee [2 ]
Kang, Nam Sook [2 ]
Yoo, Sung-Eun [2 ]
Cheon, Hyae Gyeong [1 ,2 ]
机构
[1] Gachon Univ Med & Sci, Dept Pharmacol & Pharmaceut Sci, Inchon 406799, South Korea
[2] Korea Res Inst Chem Technol, Bioorgan Sci Div, Ctr Metab Syndrome Therapeut, Taejon 305606, South Korea
关键词
KR-33749; 5-Lipoxygenase inhibitor; Antiinflammatory activity; ATOPIC-DERMATITIS; SKIN LEVELS; LEUKOTRIENE; BIOSYNTHESIS; INFLAMMATION; MEDIATORS; ASSAY; MICE;
D O I
10.1159/000315488
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background/Aim: To discover new 5-lipoxygenase (5-LO) inhibitors applicable to inflammation-related skin disease, we identified and examined antiinflammatory properties of a novel 5-LO inhibitor, KR-33749, in vitro and in vivo. Methods: 5-LO enzyme activity was assayed using insect cell lysates overexpressing rat 5-LO. The leukotriene B-4(LTB4) level was assayed in rat basophilic leukemia (RBL-1) cell line. Mouse ear edema was induced by topical application of arachidonic acid. Atopic dermatitis-like skin lesion was induced by topical application of 1-chloro-2,4-dinitrobenzene (DNCB) to NC/Nga mice. Results: KR-33749 inhibited 5-LO activity with an IC50 value of 70.5 +/- 6.0 nmol/l in parallel with LTB4 inhibition in RBL-1 cells. The compound exhibited a >1,000-fold selectivity against 12-LO and 15-LO. KR-33749 showed in vivo protective effects against arachidonic acid-induced ear edema and DNCB-induced atopic dermatitis-like symptoms in NC/Nga mice. Conclusion: Our results show that KR-33749, a new 5-LO inhibitor exhibits potent antiinflammatory activities in vitro as well as in vivo. Copyright (C) 2010 S. Karger AG, Basel
引用
收藏
页码:65 / 72
页数:8
相关论文
共 29 条
[1]   Impairment of skin barrier function in NC/Nga Tnd mice as a possible model for atopic dermatitis [J].
Aioi, A ;
Tonogaito, H ;
Suto, H ;
Hamada, K ;
Ra, C ;
Ogawa, H ;
Maibach, H ;
Matsuda, H .
BRITISH JOURNAL OF DERMATOLOGY, 2001, 144 (01) :12-18
[2]   MEASUREMENT OF CUTANEOUS INFLAMMATION - ESTIMATION OF NEUTROPHIL CONTENT WITH AN ENZYME MARKER [J].
BRADLEY, PP ;
PRIEBAT, DA ;
CHRISTENSEN, RD ;
ROTHSTEIN, G .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1982, 78 (03) :206-209
[3]  
BRAIN SD, 1982, LANCET, V2, P762
[4]   Modulators of leukotriene biosynthesis and receptor activation [J].
Brooks, CDW ;
Summers, JB .
JOURNAL OF MEDICINAL CHEMISTRY, 1996, 39 (14) :2629-2654
[5]   Application of the ferrous oxidation-xylenol orange assay for the screening of 5-lipoxygenase inhibitors [J].
Cho, YS ;
Kim, HS ;
Kim, CH ;
Cheon, HG .
ANALYTICAL BIOCHEMISTRY, 2006, 351 (01) :62-68
[6]  
Dajani EZ, 2008, J PHYSIOL PHARMACOL, V59, P117
[7]   Clinical pharmacology of leukotriene receptor antagonists and 5-lipoxygenase inhibitors [J].
Drazen, J .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1998, 157 (06) :S233-S237
[8]   Eicosanoids in inflammatory skin diseases [J].
Fogh, K ;
Kragballe, K .
PROSTAGLANDINS & OTHER LIPID MEDIATORS, 2000, 63 (1-2) :43-54
[9]   LEUKOTRIENE-B, A POTENT CHEMOKINETIC AND AGGREGATING SUBSTANCE RELEASED FROM POLYMORPHONUCLEAR LEUKOCYTES [J].
FORDHUTCHINSON, AW ;
BRAY, MA ;
DOIG, MV ;
SHIPLEY, ME ;
SMITH, MJH .
NATURE, 1980, 286 (5770) :264-265
[10]   Prostaglandins and leukotrienes: Advances in eicosanoid biology [J].
Funk, CD .
SCIENCE, 2001, 294 (5548) :1871-1875